BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543-2548. [PMID: 18668587 DOI: 10.1002/art.23696] [Cited by in Crossref: 116] [Cited by in F6Publishing: 87] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Elmholdt T, Buus N, Ramsing M, Olesen A. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial: Imatinib mesylate with antifibrotic effect in nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology 2013;27:779-84. [DOI: 10.1111/j.1468-3083.2011.04398.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
2 Asano Y. Future treatments in systemic sclerosis. The Journal of Dermatology 2010;37:54-70. [DOI: 10.1111/j.1346-8138.2009.00758.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 7.7] [Reference Citation Analysis]
3 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 6.9] [Reference Citation Analysis]
4 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
5 Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JHW. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24. [DOI: 10.1002/art.24186] [Cited by in Crossref: 145] [Cited by in F6Publishing: 123] [Article Influence: 12.1] [Reference Citation Analysis]
6 Asano Y, Bujor AM, Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci 2010;59:153-62. [PMID: 20663647 DOI: 10.1016/j.jdermsci.2010.06.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
7 Poisson JL, Low A, Park YA. The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange: Treatment of Nephrogenic Systemic Fibrosis With TPE. J Clin Apheresis 2013;28:317-20. [DOI: 10.1002/jca.21253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
8 Paniagua RT, Fiorentino DF, Chung L, Robinson WH. Tyrosine kinases in inflammatory dermatologic disease. J Am Acad Dermatol 2011;65:389-403. [PMID: 20584561 DOI: 10.1016/j.jaad.2010.04.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
10 Gordon J, Spiera R. Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies. Int J Rheumatol 2011;2011:842181. [PMID: 22013450 DOI: 10.1155/2011/842181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
12 Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009;5:200-6. [PMID: 19337284 DOI: 10.1038/nrrheum.2009.26] [Cited by in Crossref: 202] [Cited by in F6Publishing: 179] [Article Influence: 16.8] [Reference Citation Analysis]
13 Liu Z, Fang H, Slikker W, Tong W. Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. Trends in Pharmacological Sciences 2016;37:843-57. [DOI: 10.1016/j.tips.2016.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
14 Moinzadeh P, Hunzelmann N, Krieg T. Pharmacology and rationale for imatinib in the treatment of scleroderma. J Exp Pharmacol 2013;5:15-22. [PMID: 27186133 DOI: 10.2147/JEP.S26894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
15 Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res 2020;37:167. [PMID: 32778962 DOI: 10.1007/s11095-020-02851-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 39.0] [Reference Citation Analysis]
16 Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 2011;24:386-95. [PMID: 21910796 DOI: 10.1111/j.1529-8019.2011.01431.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 37] [Article Influence: 7.1] [Reference Citation Analysis]
17 Boyd AS, Sanyal S, Abraham JL. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? J Am Acad Dermatol 2010;62:337-42. [PMID: 19939504 DOI: 10.1016/j.jaad.2009.04.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
18 Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology 2011;64:91-6. [DOI: 10.1016/j.jaad.2009.12.044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
19 Ong VH, Denton CP. Investigative Approaches to Drug Therapy. In: Varga J, Denton CP, Wigley FM, editors. Scleroderma. Boston: Springer US; 2012. pp. 603-13. [DOI: 10.1007/978-1-4419-5774-0_50] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
21 Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol. 2009;16:897-905. [PMID: 19375360 DOI: 10.1016/j.acra.2009.01.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
22 Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic Systemic Fibrosis and Its Impact on Abdominal Imaging. RadioGraphics 2009;29:1565-74. [DOI: 10.1148/rg.296095517] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
23 Hinz B. Targeting the myofibroblast to improve wound healing. Wound Healing Biomaterials. Elsevier; 2016. pp. 69-100. [DOI: 10.1016/b978-1-78242-455-0.00003-3] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-878. [PMID: 21091117 DOI: 10.2217/imt.10.69] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
25 Blaha T, Nigwekar S, Combs S, Kaw U, Krishnappa V, Raina R. Dermatologic manifestations in end stage renal disease. Hemodial Int 2019;23:3-18. [PMID: 30520561 DOI: 10.1111/hdi.12689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Li JX, Fu LJ, Yang XG, Wang K. Integrin-mediated signaling contributes to gadolinium-containing-particle-promoted cell survival and G₁ to S phase cell cycle transition by enhancing focal adhesion formation. J Biol Inorg Chem 2012;17:375-85. [PMID: 22086330 DOI: 10.1007/s00775-011-0859-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Burrows NP, Lovell CR. Disorders of Connective Tissue. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-70. [DOI: 10.1002/9781444317633.ch45] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
28 Swaminathan S, Arbiser JL, Hiatt KM, High W, Abul-ezz S, Horn TD, Shah SV. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: Possible role of phospho-70-ribosomal-S6 kinase. Journal of the American Academy of Dermatology 2010;62:343-5. [DOI: 10.1016/j.jaad.2009.04.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
29 Leung N, Shaikh A, Cosio FG, Griffin MD, Textor SC, Gloor JM, Schwab TR, Larson TS, Dean PG, Prieto M, Nyberg SL, Stegall MD, Lee CU, Pittelkow MR. The Outcome of Patients with Nephrogenic Systemic Fibrosis after Successful Kidney Transplantation. American Journal of Transplantation 2010;10:558-62. [DOI: 10.1111/j.1600-6143.2009.02959.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
30 Olivieri J, Coluzzi S, Attolico I, Olivieri A. Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. ScientificWorldJournal 2011;11:1908-31. [PMID: 22125447 DOI: 10.1100/2011/924954] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
31 Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience. Journal of the American Academy of Dermatology 2010;63:389-99. [DOI: 10.1016/j.jaad.2009.10.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012;19:806-11. [PMID: 22571387 DOI: 10.1111/j.1442-2042.2012.03042.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
33 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
34 Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61:868-874. [PMID: 19836645 DOI: 10.1016/j.jaad.2009.03.040] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
35 Wermuth PJ, Jimenez SA. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). PLoS One 2018;13:e0196559. [PMID: 29718973 DOI: 10.1371/journal.pone.0196559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
36 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
37 Ivey MJ, Kuwabara JT, Riggsbee KL, Tallquist MD. Platelet-derived growth factor receptor-α is essential for cardiac fibroblast survival. Am J Physiol Heart Circ Physiol 2019;317:H330-44. [PMID: 31125253 DOI: 10.1152/ajpheart.00054.2019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
38 Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol 2013;35:351-6. [PMID: 23051628 DOI: 10.1097/DAD.0b013e31826c5508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028-1040. [PMID: 22772564 DOI: 10.1038/nm.2807] [Cited by in Crossref: 1669] [Cited by in F6Publishing: 1475] [Article Influence: 185.4] [Reference Citation Analysis]
40 Igreja ACDSM, Mesquita KDC, Cowper SE, Costa IMC. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol 2012;87:597-607. [DOI: 10.1590/s0365-05962012000400013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Distler JH, Distler O. Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) 2009;48:2-4. [PMID: 19029132 DOI: 10.1093/rheumatology/ken431] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
42 Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5:157-170. [PMID: 19190625 DOI: 10.1038/ncpneph1040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
43 Panesar M, Yacoub R. What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis? Seminars in Dialysis 2011;24:373-4. [DOI: 10.1111/j.1525-139x.2011.00913.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
45 Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43. [PMID: 20663970 DOI: 10.1148/radiol.10091131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
46 Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol 2010;183:27-33. [PMID: 19913804 DOI: 10.1016/j.juro.2009.09.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
47 Galperin TA, Cronin AJ, Leslie KS. Cutaneous manifestations of ESRD. Clin J Am Soc Nephrol. 2014;9:201-218. [PMID: 24115194 DOI: 10.2215/cjn.05900513] [Cited by in Crossref: 32] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
48 Gordon J, Spiera R. Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations. Curr Rheumatol Rep 2011;13:51-8. [DOI: 10.1007/s11926-010-0146-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
49 Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep 2012;14:39-46. [PMID: 22131103 DOI: 10.1007/s11926-011-0220-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
50 Wallace E, Gewin L. Imatinib: Novel Treatment of Immune-Mediated Kidney Injury. JASN 2013;24:694-701. [DOI: 10.1681/asn.2012080818] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
51 Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis. Mol Aspects Med 2018;62:44-62. [PMID: 29155002 DOI: 10.1016/j.mam.2017.11.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
52 Iwamoto N, Distler JHW, Distler O. Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials. Curr Rheumatol Rep 2011;13:21-7. [DOI: 10.1007/s11926-010-0142-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
53 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
54 Karcaaltincaba M, Oguz B, Haliloglu M. Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. Pediatr Radiol 2009;39 Suppl 3:382-4. [PMID: 19440757 DOI: 10.1007/s00247-009-1236-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
55 Hope TA, Leboit PE, High WA, Fu Y, Brasch RC. Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. Magnetic Resonance Imaging 2013;31:139-44. [DOI: 10.1016/j.mri.2012.06.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
56 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
57 Kaewlai R, Abujudeh H. Nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2012;199:W17-W23. [PMID: 22733927 DOI: 10.2214/ajr.11.8144] [Cited by in Crossref: 78] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
58 Yaqub A, Chung L, Rieger KE, Fiorentino DF. Localized cutaneous fibrosing disorders. Rheum Dis Clin North Am 2013;39:347-64. [PMID: 23597968 DOI: 10.1016/j.rdc.2013.02.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
59 Hutchison N, Fligny C, Duffield JS. Resident mesenchymal cells and fibrosis. Biochim Biophys Acta 2013;1832:962-71. [PMID: 23220259 DOI: 10.1016/j.bbadis.2012.11.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
60 Horton JA, Chung EJ, Hudak KE, Sowers A, Thetford A, White AO, Mitchell JB, Citrin DE. Inhibition of radiation-induced skin fibrosis with imatinib. Int J Radiat Biol 2013;89:162-70. [PMID: 23083077 DOI: 10.3109/09553002.2013.741281] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
61 Cordova KB, Oberg TJ, Malik M, Robinson-bostom L. Dermatologic Conditions Seen in End-Stage Renal Disease. Seminars in Dialysis 2009;22:45-55. [DOI: 10.1111/j.1525-139x.2008.00534.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
62 Schmidt-Lauber C, Harrach S, Pap T, Fischer M, Victor M, Heitzmann M, Hansen U, Fobker M, Brand SM, Sindic A, Pavenstädt H, Edemir B, Schlatter E, Bertrand J, Ciarimboli G. Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis. PLoS One 2012;7:e52247. [PMID: 23284953 DOI: 10.1371/journal.pone.0052247] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
63 Motegi S, Okada E, Uchiyama A, Yamada K, Ogino S, Yokoyama Y, Takeuchi Y, Monma F, Suzuki T, Ishikawa O. Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. Exp Dermatol 2014;23:664-9. [DOI: 10.1111/exd.12500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
64 Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009;21:636-41. [PMID: 19726995 DOI: 10.1097/BOR.0b013e3283310d57] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
65 Beyer C, Distler JH. The scientific basis for novel treatments of systemic sclerosis. F1000 Med Rep 2009;1:95. [PMID: 20948682 DOI: 10.3410/M1-95] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77. [PMID: 20714270 DOI: 10.1097/RLI.0b013e3181e943d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
67 Swartz RD. Idiopathic Retroperitoneal Fibrosis: A Review of the Pathogenesis and Approaches to Treatment. American Journal of Kidney Diseases 2009;54:546-53. [DOI: 10.1053/j.ajkd.2009.04.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
68 Divekar AA, Khanna D, Abtin F, Maranian P, Saggar R, Saggar R, Furst DE, Singh RR. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clin Immunol 2011;141:293-303. [PMID: 22015344 DOI: 10.1016/j.clim.2011.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
69 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
70 Lima XT, Alora-palli MB, Kimball AB, Kay J. Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. Arthritis Care Res 2013;65:637-42. [DOI: 10.1002/acr.21877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
72 Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028-1040. [PMID: 22772564 DOI: 10.1038/nm.2807)] [Reference Citation Analysis]
73 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
74 Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011;70:1003-9. [PMID: 21398330 DOI: 10.1136/ard.2010.143974] [Cited by in Crossref: 114] [Cited by in F6Publishing: 89] [Article Influence: 11.4] [Reference Citation Analysis]
75 Sargin I, Akyuz L, Kaya M, Tan G, Ceter T, Yildirim K, Ertosun S, Aydin GH, Topal M. Controlled release and anti-proliferative effect of imatinib mesylate loaded sporopollenin microcapsules extracted from pollens of Betula pendula. Int J Biol Macromol 2017;105:749-56. [PMID: 28716746 DOI: 10.1016/j.ijbiomac.2017.07.093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
76 Bournia VK, Evangelou K, Sfikakis PP. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum 2013;42:377-90. [PMID: 22789835 DOI: 10.1016/j.semarthrit.2012.06.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
77 Leung N, Pittelkow MR, Lee CU, Good JA, Hanley MM, Moyer TP. Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. NDT Plus 2009;2:309-11. [PMID: 25984024 DOI: 10.1093/ndtplus/sfp042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
78 Morris MF, Zhang Y, Zhang H, Prowda JC, Silvers DN, Fawwaz RA, Prince MR. Features of nephrogenic systemic fibrosis on radiology examinations. AJR Am J Roentgenol 2009;193:61-9. [PMID: 19542396 DOI: 10.2214/AJR.08.1352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Gordon JK, Spiera RF. Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol 2010;22:690-5. [PMID: 20827202 DOI: 10.1097/BOR.0b013e32833f1105] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
80 Coelho-macias V, Mendes-bastos P, Assis-pacheco F, Cardoso J. Imatinib: a novel treatment approach for generalized morphea. Int J Dermatol 2014;53:1299-302. [DOI: 10.1111/ijd.12387] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
81 Francès C, Senet P, Lipsker D. Fibrose systémique néphrogénique. La Revue de Médecine Interne 2011;32:358-62. [DOI: 10.1016/j.revmed.2009.07.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
82 Huang X, Khoong Y, Han C, Su D, Ma H, Gu S, Li Q, Zan T. Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity? Front Physiol 2021;12:694605. [PMID: 34335301 DOI: 10.3389/fphys.2021.694605] [Reference Citation Analysis]
83 Morgan ND, Hummers LK. Scleroderma Mimickers. Curr Treatm Opt Rheumatol 2016;2:69-84. [PMID: 28473954 DOI: 10.1007/s40674-016-0038-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
84 Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J 2011;2:51-6. [PMID: 23130224 DOI: 10.4103/2229-5178.85990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
85 Bardin T, Richette P. Nephrogenic systemic fibrosis. Current Opinion in Rheumatology 2010;22:54-8. [DOI: 10.1097/bor.0b013e328333bf3d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
86 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 40] [Article Influence: 11.1] [Reference Citation Analysis]
87 Zhang Y, Distler JH. Therapeutic molecular targets of SSc-ILD. Journal of Scleroderma and Related Disorders 2020;5:17-30. [DOI: 10.1177/2397198319899013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]